Gellan Gum

ID: gellan_gum

Aliases: E418, gellan, microbial polysaccharide gellan

Type: compound

Route/form: oral food-additive polysaccharide; supplement-like NAFLD evidence is preclinical

Status: food_additive

Evidence level: preclinical

Best data tier: direct preclinical; adjacent early human

Support scope: human, non-human/mechanistic, review/regulatory

Source types: human_trial, in_vitro, preclinical, regulatory_safety

Linked sources: 4

Broad outcomes: Fat loss / metabolic health, Gut / immune / inflammation

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

Optimization domains

Research basis

Limits, risks, and missing evidence

Risk flags

Linked papers, labels, and reviews

  1. Gellan gum prevents non-alcoholic fatty liver disease by modulating the gut microbiota and metabolites
    preclinical / pubmed_gellan_gum_nafld_microbiota_2022
    Mouse NAFLD and in vitro fermentation study reporting gellan-gum effects on gut microbiota, SCFAs/metabolites, liver inflammation, and lipid metabolism.
  2. The dietary effects of gellan gum in humans
    human_trial / tandfonline_gellan_gum_human_dietary_effects_1988
    Older human dietary-effects/safety context for gellan gum exposure.
  3. Re-evaluation of gellan gum (E 418) as food additive
    regulatory_safety / efsa_gellan_gum_reevaluation_2018
    EFSA food-additive safety review; useful for additive status and human exposure context rather than efficacy.
  4. Metabolic profiles of oligosaccharides derived from four microbial polysaccharides by faecal inocula from type 2 diabetes patients
    in_vitro / pubmed_gellan_gum_oligosaccharide_fermentation_2021
    In vitro human-faecal-inocula fermentation study including gellan gum oligosaccharides and microbiome metabolite profiling.